The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients.
Overview
- Phase
- Phase 1
- Intervention
- umbilical cord Mesenchymal Stem Cells
- Conditions
- Liver Cirrhosis
- Sponsor
- Qingdao University
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- The result of liver function and liver histological improvement.
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) infusion via hepatic artery in the treatment of liver cirrhosis.
Detailed Description
To investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) infusion via hepatic artery in the treatment of liver cirrhosis. Patients with liver cirrhosis were randomly separated into two groups. Umbilical cord MSCs were infused to patients using interventional method via hepatic artery for One group. After the catheter placed at proper hepatic artery was confirmed by angiography, umbilical cord MSCs were infused slowly for 15-20minutes. The control group accepted conserved therapy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged 18\~70 years.
- •Liver cirrhosis
- •written consent
Exclusion Criteria
- •The end-stage of liver cirrhosis.
- •Severe problems in other vital organs(e.g.the heart,renal or lungs).
- •Hepatocellular carcinoma or other malignancies
- •Pregnancy
- •Presence of significant extrahepatic biliary disease (e.g. CBD stone, PSC, etc.)
- •Cardiac, renal or respiratory failure
- •Active thrombosis of the portal or hepatic veins
Arms & Interventions
umbilical cord mesenchymal stem cells
Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
Intervention: umbilical cord Mesenchymal Stem Cells
Conserved therapy
Patients received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
Intervention: Conserved therapy
Outcomes
Primary Outcomes
The result of liver function and liver histological improvement.
Time Frame: every 4 weeks
Secondary Outcomes
- The disappearance or reduction of abdominal dropsy(every 4 weeks)
- The clinical symptom improve(including food appetite,debilitation,abdominal distension,edema of lower limbs )(every 4 weeks)